Premier Research Group, the international contract research organisation with headquarters in the US and the UK, has rebranded its Medical Device business unit to D-TARGET, the name of the Swiss company whose acquisition in July 2007 boosted Premier’s offering in the sector.
Reintroducing the D-TARGET name is a way of reinforcing Premier Research’s focus on devices while highlighting “the unique capability, expertise and experience gained by its staff operating as a dedicated Medical Device Contract Research Organisation”, the company explained.
The continued growth of clinical development activity driven by increasing regulatory and commercial demands has created specific needs in the device industry, Premier said.
Full-time D-TARGET staff are located in more than 30 countries, with primary offices in Yverdon, Switzerland and Boston, US.
In addition to its clinical operational staff, the business has specialist support groups dedicated to regulatory affairs; ethical committee, competent authority and country-specific submissions; protocol writing; statistical analysis; and data management.
In March 2009, Premier Research expanded its medical device operations to include full coverage in the US under the management of Efraim Roe Kozorivitsky, executive director, medical devices.
D-TARGET was one of a string of acquisitions by Premier Research as a public traded company before it agreed in March 2008 to a takeover offer from Pegasus Bidco, an acquisition vehicle backed by private equity firm ECI Partners, financier Indigo and the Premier management.
